从AUC/MIC到AUCss和Cmin:通过基于模型的精确剂量确定,优化在重症患者中的米卡芬金治疗
Racym Berrah1, Franck Saint-Marcoux1,2, Caroline Monchaud1,2
1Pharmacology & Transplantation, Limoges University, Inserm U1248, 2 Rue du Pr Descottes, F-87000, Limoges, France.
The AAPS journal
|November 11, 2025
概括
在重症患者中,米卡金的药理动力学差异很大. 曲线下的平稳状态面积 (AUCss) 和低度 (Cmin) 比AUC/MIC更好地预测真菌感染的根除,这表明新的治疗药物监测策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- 米卡丁,一个 echinocandin,对于侵入性真菌感染至关重要.
- 它的药理动力学 (PK) 在重症监护室 (ICU) 患者中表现出显著的变化.
- 优化micafungin的剂量对于危急病患者群体的有效治疗至关重要.
研究的目的:
- 在ICU患者中描述米卡金族群PK.
- 为了确定影响米卡芬金暴露的临床因素.
- 评估AUCss和Cmin作为治疗药物监测 (TDM) 中AUC/MIC的实际替代方案.
主要方法:
- 种群PK分析使用二分区模型与第一阶段淘汰.
- 通过逐步选择进行共变量分析,以确定影响因素.
- 接收器操作特征 (ROC) 分析,以评估PK/药理动力学 (PD) 指数性能.
主要成果:
- 观察到米卡金清除的高个体间变异性 (59.9%),总 bilirubin 是一个显著的共同变量.
- 与AUC/MIC比率 (ROC AUC 0.656和0.641与0.579) 相比,AUCss和Cmin显示了微生物根除的优异预测性能.
- 达到目标AUCss (>90.15毫克·小时/升) 或Cmin (>1.22毫克/升) 与更快的真菌根除有显著的相关性.
结论:
- 在重症患者中,米卡金的暴露高度可变,受总胆红素等因素的影响.
- AUCss和Cmin是有希望的,MIC独立的指标,用于指导ICU设置中的micafungin治疗.
- 进一步验证这些简化监测策略可能会提高侵袭性真菌感染的治疗结果.
相关概念视频
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
226
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
226
01:20Estimation of k and VD of Aminoglycosides
205
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
205
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
141
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
141
01:21Dose Size and Dosing Frequency: Determination Methods
264
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
264
01:20Determination of Michaelis Constant and Maximum Elimination Rate
418
The Michaelis constant (KM) and the theoretical maximum process rate (Vmax) are vital parameters in the Michaelis-Menten equation, central to many biochemical reactions. They provide essential insights into enzyme kinetics and drug metabolism.
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...
418
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
200
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
200